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Abstract
Cardiomyopathies are an important and heterogeneous group of common cardiac diseases. An 
increasing number of cardiomyopathies are now recognized to have familial forms, which result 
from single-gene mutations that render a Mendelian inheritance pattern, including hypertrophic 
cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right 
ventricular cardiomyopathy and left ventricular noncompaction cardiomyopathy. Recently, clinical 
genetic tests for familial cardiomyopathies have become available for clinicians evaluating and 
treating patients with these diseases, making it necessary to understand the current progress and 
challenges in cardiomyopathy genetics and diagnostics. In this review, we summarize the genetic 
basis of selected cardiomyopathies, describe the clinical utility of genetic testing for 
cardiomyopathies and outline the current challenges and emerging developments.
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Cardiomyopathies are a heterogeneous group of heart muscle diseases associated with 
mechanical and/or electrical dysfunction that predispose patients to sudden cardiac death 
[1,2]. Familial cardiomyopathies are typically diagnosed in the third or fourth decades of 
life, but may present at any age. Over the last 20 years, and at an ever quickening pace in 
recent years, the association of specific genes involved with cardiomyopathies has 
illuminated their pathophysiology and identified potential therapeutic targets that may one 
day allow clinicians to stall, regress or even prevent certain cardiomyopathies. Hypertrophic 
cardiomyopathy (HCM), dilated cardiomyopathy (DCM), restrictive cardiomyopathy 
(RCM), left ventricular noncompaction cardiomyopathy (LVNC), and arrhythmogenic right 
ventricular cardiomyopathy (ARVC) are all now recognized to have a genetic component 
(TABLE 1). The identification of cardiomyopathy-susceptibility genes has enabled the 
development of diagnostic tests that can identify genetic mutations underlying disease in a 
substantial portion of patients. The ability to identify disease-causing genetic mutations is 
still quite limited, largely due to the lack of complete knowledge of all the mutations and 
affected genes that lead to cardiomyopathies. Whenever disease-causing mutations are 
identified, family members at-risk for developing a cardiomyopathy can be determined, 
including those in which little or no clinical suspicion exists.
The recent transition of cardiomyopathy genetic testing from research laboratories into 
clinical practice highlights the need for the education of clinicians in the state of the art and 
the implications of cardiomyopathy genetic testing. This review summarizes the genetic 
basis of selected cardiomyopathies, describes the clinical utility of genetic testing for 
cardiomyopathies and outlines the current challenges and emerging developments in clinical 
genetic testing for cardiomyopathies.
Molecular basis of familial cardiomyopathies
Cardiomyopathies are largely monogenic disorders in which pathogenic mutations and 
disease susceptibility follow predictable Mendelian modes of transmission. In monogenic, or 
‘single-gene’, disorders, disease-causing mutations in a particular individual are restricted to 
a single gene. The mutations typically consist of an alteration of a single nucleotide that 
causes one amino acid within the encoded protein to be substituted for another. 
Alternatively, the mutation may be the deletion or insertion of a short sequence of 
nucleotides that results in a truncated protein. Autosomal dominant inheritance, in which a 
single mutation affecting one copy of an autosomal gene causes disease that may affect 
either gender, is the most commonly observed inheritance pattern in cardiomyopathies. 
Although far less frequent and differing among the specific diseases and genes involved, 
autosomal recessive and X-linked inheritance patterns are also observed in 
cardiomyopathies. The phenomenon of age-dependent penetrance, where only a portion of 
carriers of a disease-causing mutation clinically manifest disease, can confound recognition 
of a cardiomyopa-thy as a familial disease. Familial cardiomyopathies affect all ethnicities. 
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There is no broad ethnic predisposition outside of small, isolated populations affected by 
specific founder mutations. The precise molecular mechanisms and pathological processes 
leading from single-gene mutations to the development of clinically recognizable 
cardiomyopathies is still largely unknown; however, the identification and characterization 
of many mutations across many genes has begun to uncover the diverse molecular 
mechanisms leading to seemingly similar disease manifestations. Cardiomyopathies were 
initially defined clinically and their diagnosis and management continue to be based on 
clinical presentation, despite the genetic heterogeneity underlying these diseases. While little 
is still known regarding the causes of the heterogeneity of disease, it is known that having 
more than one type of mutation can increase the severity of disease [3]. A number of gene 
polymorphisms have also been shown to modify the severity of cardiomyopathy (for a recent 
review see [4]). Complicating the genetic diagnosis of cardiomyopathies is the realization 
that different mutations in a single gene can lead to two different cardiomyopathic 
phenotypes. For example, different mutations in cardiac troponin, cardiac troponin T, and α-
cardiac actin can cause RCM or HCM (TABLES 2 & 3). Similarly, different mutations in 
lamin A/C can lead to LVNC or DCM phenotypes (TABLES 2 & 4).
Arrhythmogenic right ventricular cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy is estimated to affect one in 5000 
individuals and is characterized by life-threatening arrythmias due to fatty infiltration and 
scarring of the right or both ventricles [5]. ARVC is an autosomal dominant disease with 
variable penetrance [6]. The replacement of right ventricular myocardium by fibrofatty 
tissue progresses over time, leading to ventricular wall thinning and aneurysms [7–9]. The 
fibrofatty infiltrates also interfere with the conduction of electrical impulses, causing 
characteristic changes in the electrocardiogram (ECG), including epsilon waves (FIGURE 
1), late potentials, right bundle branch block and ventricular arrhythmias. Cell death can be 
seen by histology, frequently associated with inflammatory infiltrates and life-threatening 
arrhythmias [7–11]. The left ventricle is involved in nearly 50% of all cases, generally in the 
postero–lateral subepicardium [7,9]. Cell death can be seen by histology, frequently 
associated with inflammatory infiltrates and life-threatening arrhythmias [7–11]. The 
inflammatory cells may be a reaction to cell death and cardiotropic viruses have been 
reported in the myocardium of some patients with ARVC, suggesting a role for infectious 
etiologies in the pathogenesis of disease [12,13].
Recently, it has been discovered that ARVC is largely a disease of the desmosome. The 
desmosome is a group of cellular structures that mechanically couple cardiomyocytes to 
transmit contractile force (FIGURE 2). The prevailing view of ARVC pathogenesis is that 
disruption of the desmosome leads to progressive myocyte separation, myocyte death and 
subsequent replacement of dead cells with fat and scar tissue. However, mechanisms 
involving aberrant regulation of adipogenesis signaling pathways have also been proposed 
[14–16]. Mutations in five genes making up the desmosome (FIGURE 2) are found in 
approximately 50% of clinically diagnosed ARVC patients, including the genes desmoplakin 
(DSP), plakophilin-2 (PKP2), desmoglein-2 (DSG2), desmocollin-2 (DSC2), and 
plakoglobin (PKG) (TABLE 2) [17]. The PKP2 gene is most frequently mutated in 43% of 
cases (70% of proven familial cases) [18–22]. Mutations in extradesmosomal genes, such as 
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TGFβ3 have also been associated with ARVC [23]. Recently, a founder mutation in the gene 
transmembrane protein 43 (TMEM43) was shown to be the cause of ARVC in 15 unrelated 
families, all with complete penetrance [24]. Whether the protein encoded by TMEM43 is a 
component of the desmosome is not yet known and its association with ARVC may lead to 
the discovery of a novel disease mechanism. There are a number of notable diseases that 
lead to clinical entities that mimic the findings of ARVC; that is, diseases that phenocopy 
ARVC. The closest phenocopy of ARVC is myotonic dystrophy [25], but sarcoidosis also 
can closely mimic ARVC [26]. This suggests an important role for genetic testing (for 
unstable CTG repeats in the DMPK gene) and biopsy (for sarcoid) also in distinguishing 
ARVC cases. The importance of the desmosome in the pathogenesis of ARVC may be 
highlighted in recent studies, which have identified a role for immunohistochemical analysis 
of conventional endomyocardial biopsies for desmosomal plakoglobin [27]. In ten out of 11 
ARVC cases, a decrease in immunoreactive plakoglobin was identified, a finding not seen in 
control samples in blinded studies [27]. This diffuse reduction in plakoglobin demonstrated 
a sensitivity of 91% and a specificity of 82% (positive predictive value: [PPV] = 83%; 
negative predictive value [NPV] = 90%). While a number of proteins may be involved in the 
pathogenesis of ARVC, the ability of these proteins to stabilize the desmosome, regardless 
of their origin, may be key to the pathogenesis of ARVC.
Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy is the most common genetic heart disease in the USA, 
affecting one in 500 people [28,29]. The diagnosis of HCM is made primarily on patient 
history, physical examination, echocardiography and ECG, identifying hypertrophy in the 
absence of underlying primary disease (FIGURE 3). There is a spectrum of symptoms in 
HCM patients: some patients may be asymptomatic their entire life, while others may 
present with dyspnea, syncope, chest pain or sudden cardiac death due to mechanical or 
electrical abnormalities [30–33]. Despite its namesake, sudden cardiac death can occur in 
HCM patients with little or no cardiac hypertrophy due to the histological hallmark of 
myocardial disarray, which can act as an arrhythmogenic substrate resulting in life-
threatening arrhythmias [34–36]. There is a high degree of disease heterogeneity in HCM 
and in contrast to other genetic diseases, HCM has a preponderance of private, familial 
mutations and a lack of mutational hot spots within causative genes.
Nearly 50–60% of HCM cases have mutations in genes encoding proteins that constitute the 
sarcomere, the fundamental contractile unit of cardiac myocytes (FIGURE 1 & TABLE 3) 
[4]. More than 450 mutations in 20 genes that cause HCM have been described to date [37]. 
The genes most commonly affected are cardiac myosin binding protein C (MYBPC3), 
cardiac β-myosin heavy chain (MYH7), and cardiac troponin isoforms I (TNNI3) and T 
(TNNT2) (TABLE 3). Two mechanisms have been hypothesized to cause HCM. The 
affected protein may affect the heart by acting as a dominant negative ‘poison peptide’, 
disrupting function of the wild-type protein by its presence. Alternatively, mutations in 
sarcomere proteins may lead to haploinsufficiency [38]. In this scenario, it is hypothesized 
that mutations in one gene do not allow the sarcomere to be stoichiometrically balanced, 
resulting in poor performance of the remaining sarcomere [37,39]. Recent studies further 
suggest a disruption in protein quality control mechanisms may also play a causative role in 
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disease [40]. Sarcomere mutations responsible for HCM result in impaired relaxation of the 
heart and significant changes in calcium signaling [41–45] and may also result in metabolic 
defects [46], which could play a role in the increased susceptibility of patients with HCM 
mutations to sudden cardiac death.
Dilated cardiomyopathy
Dilated cardiomyopathy is defined clinically by left ventricular dilation and reduced 
contractile performance (FIGURE 4). DCM is the most frequent diagnosis leading to heart 
transplantation in the USA [2,47]. There are a number of known causes of DCM, including 
coronary artery disease, thyroid disease, viral myocarditis and excessive alcohol intake. 
Idiopathic DCM, that is, DCM in which common acquired/nongenetic causes are excluded, 
is estimated to affect one in 2500 individuals with 20–50% of these estimated to have a 
genetic cause [48–56]. The genetic causes of DCM are particularly heterogeneous. To date, 
mutations in more than 30 genes account for disease in approximately 25% of patients 
(FIGURE 1 & TABLE 4). Candidate gene analyses have identified causative mutations in 
cardiac actin and other sarcomere genes [57], including MYH7 [58], MYBPC3, titin (TTN), 
α-tropomyosin (TPM1) [59] and TNNT2 and TNNC1 [58,60,61]. Several subgroups of 
DCM have been identified based on distinguishing clinical features associated with gene 
mutations [62–64]. Mutations in lamin A/C (LMNA) have been associated with autosomal 
dominant DCM with conduction disease [65,66], autosomal dominant and recessive Emery 
Dreifuss Muscular Dystrophy [67,68], and autosomal dominant limb-girdle muscular 
dystrophy type 1B [69,70]. While there appears to be a continuum of muscular dystrophy 
associated with DCM, the underlying mechanism for LMNA mutations in cardiac and 
extracardiac manifestations, such as the skeletal muscle, is not known.
Interestingly, HCM and DCM share partially overlapping molecular etiologies, as both may 
result from sarcomeric mutations, although the specific mutations associated with each and 
resulting molecular consequences can be different. Functional studies of different HCM- and 
DCM-associated mutations occurring within the same sarcomeric genes suggest that, in 
general, mutations that increase sensitivity of the cardiac sarcomere to calcium result in 
HCM, whereas desensitizing mutations result in DCM [71–74].
Left ventricular noncompaction cardiomyopathy & restrictive cardiomyopathy
Although LVNC was first described in 1900, it has only recently been recognized as a 
distinct clinical entity [1,2]. It is characterized by a pattern of prominent trabecular 
meshwork and deep intratrabecular recesses communicating with the cavity of the left 
ventricle (FIGURE 2). This is thought to be due to an arrest of myocardial morphogenesis 
during cardiac development [75,76]. LVNC is a rare disease, affecting less than 0.3% of the 
population [77,78], or an annual incidence in children of 0.1 per 100,000 [79,80]. The 
clinical manifestations of LVNC can range from asymptomatic to a progressive deterioration 
of cardiac function, arrhythmias, thromboembolic events and sudden cardiac death 
[75,77,81–83]. Approximately 40% of LVNC patients have evidence of familial disease, 
with a wide genetic heterogeneity [82].
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The mainstay of diagnosis for LVNC has historically been echocardiography, as shown in 
FIGURE 5 [84]. The diagnostic criteria for LVNC include the lack of coexisting 
cardiovascular abnormalities, segmental left ventricular wall thickening with a thin 
compacted epicardial layer and a thicker noncompacted endocardial layer, an end-systolic 
noncompacted-to-compacted myocardial ratio greater than 2, and the identification of flow 
on color Doppler within the deep intratrabecular recesses [85]. Additional echocardiographic 
findings may include a decreased fractional shortening, impaired diastolic function, 
abnormal papillary muscle architecture and the presence of thrombi [85]. LVNC has been 
associated with mutations in a number of genes, including LIM domain binding protein 3 
(LDB3/ZASP), dystrobrevin-α (DTNA), tafazzin (TAZ/G4.5) and lamin A/C (LMNA) [86–
92]. Mutations in the sarcomere protein genes MYH7, TNNT2 and α-cardiac actin (ACTC) 
have also been associated with LVNC (TABLE 2) [86–92]. The more common genes 
reported in LVNC have been genes that encode for proteins found in the sarcomere (MYH7, 
TNNT2 and ACTC) [92,93].
Restrictive cardiomyopathy is characterized by an increase in cardiac wall stiffness, leading 
to decreased diastolic function with preserved systolic function. Patients generally develop 
symptoms of severe heart failure over a relatively short period of time, with the majority 
dying within a few years if they are unable to obtain a heart transplant [94]. Adult patients 
with RCM present with dyspnea, fatigue and a limited capacity to exercise [95], while 
children may present with failure to thrive, fatigue and sometimes syncope [96,97]. Chest 
radiography generally shows a normal sized heart with enlarged atria and varying degrees of 
pulmonary edema. On ECG, large P waves indicative of atrial enlargement may be present 
along with ST segment and T-wave abnormalities. By echocardiography, enlarged atria with 
impaired systolic function may be seen, and Doppler velocities may be indicative of a 
significant diastolic dysfunction. Many etiologies underlie RCM, including inflammatory 
(endomyocardial fibrosis), infiltrative (e.g., amyloidosis), storage (e.g., hemochromatosis) 
and idiopathic (reviewed in [94]). Since 1992, a number of reports have identified mutations 
in sarcomere genes underlying RCM, including TNNI3, TNNT2, MYH7 and ACTC [98–
103].
Uncovering the genetic basis and molecular mechanisms of RCM and LVNC has been 
challenging since they are far less prevalent than HCM or DCM [104,105]. Several of the 
same genes described for HCM or DCM are also associated with RCM and LVNC (TABLE 
2) [87,92,100,104,106,107]. This may indicate that RCM is a later spectrum of other 
clinically defined cardiomyopathies, or may indicate mutation-specific phenotypes. Much 
work is needed to delineate the molecular basis of familial RCM and LVNC in the context of 
other more common and well-defined cardiomyopathies.
General considerations for genetic testing of familial cardiomyopathies
Specific guidelines for the diagnosis, including the molecular diagnosis, and management of 
ARVC, HCM, DCM, LVNC and RCM have been written as expert opinions or consensus 
statements [1,108–110]. In general, physicians diagnosing and managing patients with 
cardiomyopathies should initially obtain a family history of at least three family generations 
[1]. Additional screening of at-risk family members with echocardiogram, ECG, history, 
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physical examination and other tests may be warranted. It is important that genetic 
counseling takes place in parallel with these studies to ensure the patient understands the 
heritable basis of disease, the age at which the diseases might present and the presenting 
symptoms. The role of genetic counseling in genetic testing has never been more important 
because of our incomplete understanding of the genetic basis of cardiomyopathies, which 
continues to evolve. Patients with cardiomyopathies need to understand the utility, 
sensitivity, analytic validity and, most importantly, the implications of the test results [1]. A 
final component to the evaluation of cardiomyopathies is the consideration of genetic 
testing.
A recent practice guideline published by the Heart Failure Society of America provides 
graded recommendations for clinical genetic testing of cardiomyopathies [1]. For each 
cardiomyopathy evaluated by the guideline, the value of genetic testing of an affected 
individual is considered for its role in facilitating family screening and identification of at-
risk relatives. The value was given a letter grade based on the current clinical and genetic 
knowledge, where the letter grade A corresponds to the highest score while C is the lowest. 
Genetic testing for HCM and ARVC were both given A level recommendations, genetic 
testing for DCM was given B level recommendation and genetic testing for RCM and LVNC 
were given C level recommendations [1].
If a disease-causing mutation is identified in a cardiomyopathy patient through genetic 
testing, then testing of family members can accurately predict the risk of those family 
members [1]. For an asymptomatic family member who is negative for their relative’s 
disease-causing mutation, that family member’s risk for developing the cardiomyopathy is 
considered to be the same level of risk as the general population and such individuals can 
forgo ongoing clinical screening for disease development [1]. Conversely, an asymptomatic 
family member who is positive for their relative’s disease-causing mutation is at 
substantially increased risk for developing the cardiomyopathy and should undergo 
continued clinical surveillance for disease development [1]. Genetic testing and targeted 
clinical surveillance of at-risk family members facilitates diagnosis during the early states of 
disease development and enables earlier clinical interventions. Nearly 40% of ARVC 
patients experience sudden cardiac death as their first clinical manifestation, however, with 
an early diagnosis and appropriate monitoring or treatment, often involving an implantable 
cardioverter defibrillator (ICD), most ARVC patients have an excellent prognosis [5,111–
113]. Similarly, in DCM patients, where symptoms generally manifest after the disease has 
progressed to end-stage and the 5-year survival post-diagnosis is 50%, an early diagnosis 
allows for pharmacological treatments that may prevent disease progression and reduce 
complications or lead to transplantation [114]. In addition to confirming a diagnosis in a 
cardiomyopathy patient and identifying at-risk family members, genetic testing may also be 
useful for assessing the risk for conduction defects (ARVC, DCM), distinguishing the 
underlying cause of heart failure (DCM) and distinguishing other causes of adaptive 
hypertrophy with cardiomyopathies (HCM).
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Genetic testing for ARVC
The Heart Failure Society of America assigned the grade of A for genetic testing of the one 
most clearly affected person in a family to facilitate screening and management of ARVC 
[1]. Although ARVC is a rare condition, analysis of a small number of genes can identify a 
significant proportion of cases. The testing modality most commonly applied by laboratories 
is DNA sequence analysis of the entire coding region or select exons of genes in which 
causative mutations have been identified (TABLE 5). Comprehensive sequence analysis of 
large regions of these genes is necessary due to allelic heterogeneity (multiple different 
mutations associated with disease) and the many ‘private’ mutations (mutations found in a 
single family) that can be present [5]. Sequencing of known ARVC-associated genes may 
identify mutations in as many as 50–55% of ARVC patients [5,17,115]. The 1994 Task 
Force diagnostic guidelines do not include genetic testing as a diagnostic criterion since they 
were developed in the pre-genetics era [116]. However, genetic testing may play an 
important role in ARVC diagnosis because the nonspecific features of ARVC render it 
difficult to diagnose, especially in the early disease stages [5]. Therefore, genetic testing for 
ARVC can fulfill an important role in the interpretation of borderline clinical investigations, 
as well as facilitate early diagnosis of family members potentially at-risk for developing 
ARVC. While risk for cardiac events or disease severity cannot be predicted based on 
specific mutations (i.e., genotype/ phenotype correlations), a recent genetic and clinical 
analysis of 82 clinically confirmed or suspected ARVC patients found that, in general, those 
patients with desmosomal mutations had an earlier onset of ARVC and were more likely to 
have ventricular tachycardia [17].
Several diseases mimic ARVC, which are important to recognize and rule out. These 
phenocopy diseases include myotonic dystrophy, which most closely mimics ARVC [25]. 
Myotonic dystrophy is caused by the unstable expansion of CTG trinucleotide repeats in the 
untranslated DMPK gene (encoding myotonic dystrophy protein kinase), localized to the 
intercalated disks of the cardiac muscle in proximity to gap junctions [117]. Similarly, 
sarcoidosis can mimic ARVC [26] and should be considered in the process of diagnosing 
disease.
Genetic testing for HCM
Molecular testing for HCM is the most established of the cardiomyopathies and has strong 
evidence to support clinical genetic testing [1]. The Heart Failure Society of America 
assigned the grade of A for genetic testing of the one most clearly affected person in a 
family to facilitate screening and management of HCM [1] (see also related recent reviews 
[118,119]). Clinical genetic testing is available for more than 20 HCM-susceptibility genes; 
however, analysis of two genes, MYH7 and MYBPC3, account for the majority of mutations 
that are identified in HCM patients (TABLES 3 & 5). Mutations in MYH7 and MYBPC3 
account for approximately 80% of all genotype-positive HCM patients [120]. Genetic testing 
of the eight genes most commonly associated with HCM, which all encode components of 
the cardiac sarcomere, identify mutations in 35–65% of patients that meet the clinically 
accepted definition of HCM [118]. While strict gene- and genotype–phenotype correlations 
have been attempted, definitive relationships between the mutated gene and disease 
manifestation are not generally thought to exist across all populations. For example, based 
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on studies of single mutations in large families or small cohorts, MYBPC3 mutations have 
gained the reputation of causing later onset disease, MYH7 mutations with earlier 
manifestation of disease, and TNNT2 mutations with mild LVH and increased risk of sudden 
death in some families [30,31,35,121–125]. However, in unrelated HCM cases where many 
rare, private mutations exist, the two most common forms of HCM caused by mutations of 
MYH7 and MYBPC3 are phenotypically indistinguishable in terms of age at diagnosis, 
extent of hypertrophy and family history [126,127]. HCM cases with MYH7 mutations have 
been reported with reputed TNNT2-like features of mild hypertrophy and early SCD, while 
other HCM cases with TNNT2 mutations have been shown to exhibit left ventricular 
hypertrophy with thickening of more than 3 cm [36,128]. Moreover, recurrent identification 
and analysis of identical mutations in unrelated HCM cases indicate that the prognostic 
implications of specific mutations, as well as of specific genes, must be assigned with great 
caution [126–129]. Interestingly, a recent prospective analysis of a large cohort of unrelated 
Italian HCM patients showed that HCM patients with a mutation in any one of eight 
myofilamentous sarcomeric genes (MYPBC3, MYH7, MYL2, MYL3, TNNT2, TNNI3, 
TPM1 and ACTC) were at increased risk for cardiovascular death, nonfatal ischemic stroke, 
or progression to severe heart failure symptoms compared with HCM patients with a 
negative genetic test result [130]. In a multivariate model that included established risk 
predictors in HCM, the presence of a myofilamentous sarcomeric gene mutation was 
associated with a more than fourfold independent increase in risk for unfavorable outcomes 
compared with patients with HCM and negative genetic test results [130], supporting a 
prognostic role for genetic testing in patients with clinically diagnosed HCM.
There are several rare diseases that mimic the phenotype of HCM that do not involve 
mutations in the sarcomere or sarcomere-associated genes. These diseases include familial 
Wolff–Parkinson–White syndrome, Anderson–Fabry disease, Pompe disease, Glycogen 
Storage disease Type III, Danon disease, LEOPARD syndrome/Noonan syndrome, and 
Frederich ataxia (for a review see [4]). It is important to recognize the differential 
phenotypes and/or perform the molecular test to identify these phenocopy diseases, as the 
treatments vary considerably. Several rare multisystem metabolic diseases, such as Danon 
disease and Anderson–Fabry disease, can present primarily with cardiac manifestations and 
mimic HCM caused by sarcomeric mutations; however, these metabolic diseases involve 
fundamentally different pathological processes and have different clinical courses and 
therapeutic strategies compared with typical HCM patients (TABLE 3) [131–133]. 
Anderson–Fabry disease is treated primarily with enzyme replacement [134], while Danon 
disease has a severe prognosis that may warrant earlier consideration of a heart transplant 
[131]. The recent Heart Failure Society of America recommends genetic testing when 
cardiomyopathy is associated with extra-cardiac manifestations (level of evidence grade A), 
as many of these HCM phenocopy diseases can be detected by genetic testing [1].
Genetic testing for DCM
The Heart Failure Society of America assigned the grade of B for genetic testing of the one 
most clearly affected person in a family to facilitate screening and management of DCM [1]. 
The recommendation for genetic testing for DCM was less strong because, although an ever-
growing number of genes have been identified in association with DCM, none is associated 
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with a significant proportion of DCM and together the currently known genes account for 
only a small percentage (~25%) of familial DCM. The analysis of 20 genes is currently 
available for patients suspected of having a genetic etiology underlying their idiopathic 
DCM, although most of these genes are infrequent causes of DCM (TABLES 4 & 5). 
Genetic testing of two genes that are the most common causes of DCM, LMNA and MYH7, 
is estimated to identify mutations in approximately 10% of idiopathic DCM patients, while 
testing of the more than 20 DCM-associated genes may account for an additional 10–15% of 
patients [1,56]. However, the frequency of LMNA mutations in DCM patients with 
conduction disease, particularly when skeletal muscle involvement is present, rises to 30–
45% [64,135,136]. Thus, testing for mutations in LMNA is recommended for patients with 
idiopathic DCM and conduction system defects based on the overall higher mutation 
frequency in this subset of patients, even if a family history of DCM is not present [1]. 
Identification of a LMNA mutation portends a particularly poor prognosis, with nearly half 
of cases with LMNA-related cardiomyopathy suffering sudden cardiac death [137,138]. 
LMNA mutations may identify patients at risk for sudden cardiac death prior to presentation 
with heart failure: eight out of 19 (42%) patients who underwent permanent pacing and ICD 
therapy solely on the basis of the presence of LMNA mutations with cardiac conduction 
defects and normal ventricular function received appropriate ICD intervention [139]. Owing 
to the extensive genetic heterogeneity and the high frequency of private mutations in DCM, 
the mainstay of molecular diagnosis in DCM is sequence analysis of entire protein-coding 
regions of multiple DCM-associated genes either by direct Sanger DNA sequencing or with 
resequencing arrays [1,140,141].
As with ARVC and HCM, there are a number of diseases that mimic DCM and these should 
be considered in DCM diagnosis. Approximately 80% of patients with Duchenne’s muscular 
dystrophy and approximately 10% with Becker’s muscular dystrophy have DCM [142]. In 
addition to the mutations in dystrophin associated with these diseases, DCM has been 
associated with mutations in intermediate filament lamin A/C, which underlie Emery–
Dreifuss muscular dystrophy with DCM [143].
Genetic testing for LVNC & RCM: is it worthwhile right now?
The Heart Failure Society of America assigned the lowest grade of C for their 
recommendation for genetic testing of the most clearly affected person in a family to 
facilitate screening and management for both LVNC and RCM [1]. These recommendations 
are largely due to the fact that there are few known genotype–phenotype correlations for 
either of these conditions [107], and only a fraction of the patients with disease have 
identifiable mutations. Collective testing of all known LVNC-associated genes may identify 
mutations in 20–25% of patients with LVNC. Identification of affected genes is primarily 
useful for identifying at-risk family members, including at-risk pregnancies. Genetic testing 
is available to identify LVNC-causing mutations in the DTNA, TAZ, LMNA and LDB3 
genes by sequence analysis of the entire coding region (TABLE 5). It is not known what 
percentage of patients with LVNC have mutations in these four genes, but mutations in 
additional genes have been identified, including FK506-binding protein (FKBP-12), MYH7, 
ACTC and TNNT2 [92,107]. The most commonly affected proteins that can be tested for in 
LVNC include MYH7, TNNT2 and ACTC based on their reported prevalence. Similarly, no 
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genotype–phenotype correlations have been described for RCM and estimates for the 
prevalence of mutations in MYH7 and TNNI3 are unavailable, as only a few studies have 
reported RCM families with mutations in these genes [99,104]. Since RCM is quite rare, it 
may be some time before large-scale studies can be performed to determine how common 
MYH7 and TNNI3 mutations are and to identify other causative genes. As more genes and 
mutations underlying LVNC and RCM are discovered, testing sensitivity will increase, thus, 
improving the clinical utility of testing. This will require identification of additional disease-
associated genes and whether any genotype–phenotype correlations exist that may help in 
the prognosis and therapeutic strategies applied to patients with these clinical phenotypes.
Challenges in genetic testing for cardiomyopathies
There are a number of challenges that arise in genetic testing for cardiomyopathies. The 
major challenges are the difficulty and cost of testing due to the large number of genes 
(locus heterogeneity) and different mutations (allelic heterogeneity) associated with each of 
the cardiomyopathies, the poor sensitivity for diagnosis of familial cardiomyopathies and the 
interpretation of the significance of individual mutations identified, particularly novel 
variants. For these reasons, it is particularly important to have good clinical correlation and 
to rule out other causes of cardiomyopathy or demonstrate strong evidence of a family 
history prior to undergoing genetic testing. Critical to this process is genetic counseling to 
ensure that the patient understands the heritability of cardiomyopathies, family screening 
recommendations, genetic testing options, and the value and interpretation of testing based 
on recent guidelines for the genetic evaluation of cardiomyopathies [1,119].
Direct DNA sequence analysis of all protein-coding regions of selected genes is the most 
common methodology applied to cardiomyopathy genetic testing. Owing to the high cost 
and labor associated with DNA sequencing of multiple large genes, mutation scanning of the 
entire (or selected) coding regions is sometimes performed, which is a less costly method of 
identifying region(s) of the gene likely harboring mutation(s). These regions can then be 
targeted for subsequent sequence analysis to identify the mutation(s) (for a review see [4]). 
In addition, some laboratories have incorporated microarray chip-based ‘resequencing’, in 
which overlapping DNA oligonucleotides specific for every possible single nucleotide 
substitution are tiled onto a custom DNA microarray chip [144–146]. The major advantage 
of microarray resequencing approaches is that multiple genes can be analyzed on a single 
chip, which allows for a significant savings in labor and cost after the initial investment in 
capital equipment and assay development. A major disadvantage of resequencing arrays is 
that novel insertions and deletions (indels) are difficult to detect, thus decreasing the 
sensitivity for mutation detection, although previously identified indels can be detected 
using specific tiled probes [144,145,147]. In the future, next-generation sequencing (NGS) 
technologies may enable clinical large-scale testing of multiple genes; at the present time 
NGS approaches are expensive and have not been well validated for clinical accuracy, so 
they are primarily useful as a research tool to identify additional genes that may be 
associated with cardiomyopathy.
Despite extensive analysis of the entire coding regions of multiple genes, not all patients are 
found to have disease-causing mutations because the genetic basis of these diseases are not 
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completely understood. For example, even in HCM, the best characterized of the 
cardiomyopathies, at least 40% of HCM patients have no identifiable mutation with current 
genetic tests [118,148]. The list of cardiomyopathy-associated genes is constantly evolving 
and sensitivity may be improved as additional genes are added; however, the inclusion of 
each additional gene may improve test sensitivity only slightly, as each gene individually 
may account for a small percentage of cases. Another possible explanation for decreased test 
sensitivity is the presence of mutations that are undetectable by commonly used approaches. 
Most genetic tests for cardiomyopathy-susceptibility genes are not designed to detect deep 
intronic mutations, large indels or gross genomic rearrangements, any of which may be 
deleterious and lead to cardiomyopathy. However, at least in the case of MYBPC3 and 
TNNT2, large deletions or rearrangements do not appear to play a role in the pathogenesis of 
HCM [149]. This contrasts with the RYR2 and LMNA gene deletions found to cause 
cardiomyopathy (ARVC and DCM, respectively), which were missed because standard 
sequencing techniques were unable to identify mutations [150,151].
Thus, because not all genetic causes of cardiomyopathy have been determined, genetic 
testing has limited sensitivity for diagnosis, despite high specificity. In practical terms, low 
test sensitivity and high specificity means that if a known disease-causing mutation is found, 
it should be considered as strong evidence for the diagnosis of familial cardiomyopathy. 
However, in cases where a disease-causing mutation is not found, the presence of familial 
cardiomyopathy cannot be ruled out, making clinical diagnosis still important. As the full 
spectrum of genetic mutations associated with the cardiomyopathies is identified, the 
sensitivity of genetic testing will continue to improve and may eventually evolve to the point 
that genetic testing is useful to ‘rule out’ a diagnosis of familial cardiomyopathy.
Another major challenge in clinical genetic testing is differentiating pathogenic mutations 
from benign ‘background’ genetic variation unrelated to disease. The human genome 
demonstrates significant genetic sequence variability, and differentiating deleterious 
mutations from benign sequence variation is a universal challenge for clinical genetic 
laboratories. The term ‘mutation’ is traditionally defined by the rarity of a genetic variant 
within a given population and not by an association with disease [152]. By this definition, 
any genetic variant with an allele frequency of less than 1% is considered a mutation, 
whereas variants present in the population with more than 1% frequency are considered 
common polymorphisms. Cardiomyopathies collectively result from mutations in more than 
30 different genes in which hundreds of mutations are already known and new mutations are 
continuously identified in suspected cardiomyopathy patients. Most of these mutations are 
so rare that they are effectively ‘family-specific’ causes of disease (private mutations). Both 
novel sequence variants and previously identified variants whose association with disease is 
not definitively established are considered ‘variants of uncertain/unknown significance’ 
(VUS) [153]. A recent example of this was reported by Christensen et al. who screened 53 
unrelated patients fulfilling Task Force criteria for ARVC for mutations in PKP2 by direct 
sequencing [154]. Seven patients carried missense mutations, which were also identified in 
healthy control populations, leaving their significance unknown at this time [154].
Multiple direct and predictive approaches have been used to distinguish disease-causing 
mutations from benign variants, including genetic testing of healthy individuals to determine 
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allele frequency, cosegregation studies to determine if disease and mutation track together 
within a family, analysis of protein sequence conservation across different species to predict 
the importance of a specific mutated amino acid for a protein’s function, prediction of the 
effect of a mutation upon mRNA splicing or translation and functional characterization of 
the mutant gene product using in vitro and in vivo model systems.
Mutation analysis of control populations of different ethnic groups is critical for aiding 
interpretation of genetic test results, as the extent and type of genetic sequence variability 
varies between evolutionarily related populations. Cohort samples from control populations 
are available, both commercially and in individual genetics laboratories, and may consist of 
fewer than a hundred individuals to more than a thousand depending on the source and 
ethnic group. Sequencing the same genomic region in approximately 350 individuals in a 
population is estimated to identify all of the common polymorphisms (those variants with at 
least a 1% allele frequency) in the entire population. However, the real challenge lies in 
distinguishing pathogenic mutations from more rare benign ‘background’ variants with less 
than 1% frequency. While sequencing just 150 individuals in a control population is 
estimated to identify 80% of variants with a frequency of at least 0.1%, confidently 
identifying all variants with a frequency of at least 0.1% in a given population requires more 
than 3000 individuals [155]. Such large control datasets do not exist for cardiomyopathy 
genes today; however, large-scale genetic variation sequencing projects, such as the 
International HapMap Project and the 1000 Genomes Project, will make gene-specific 
variation data from large numbers of individuals universally available [156,157]. As 
increasing numbers of healthy individuals have specific disease-associated genes sequenced 
as part of these projects, knowledge of the extent of normal genetic variation within these 
disease-associated genes will increase and enable more informed interpretations of novel 
variants encountered in clinical genetic testing.
A promising population-based approach for distinguishing pathogenic mutations from 
benign variants was recently described for long QT syndrome (LQTS) [158]. Enabled by an 
extensive collection of mutations identified in LQTS patients and rare variants identified in 
more than 1000 control subjects, Kapa and colleagues identified regions of high and low 
specificity for predicting the pathogenicity of novel variants within the most common 
LQTS-susceptibility genes [158]. The practical outcome of such case–control variant 
analyses is to assign disease-causing probabilities to novel, uncharacterized variants. A 
prerequisite for such analyses is large genetic databases of both case and control 
populations. While large numbers of cases have been screened for HCM mutations, similar 
numbers of control subjects have not. Fortunately, the 1000 Genomes Project will soon 
enable such analyses in the cardiomyopathy genetic testing field by publicly providing 
variant data within HCM-susceptibility genes of healthy control subjects [156,157].
Another approach to determine whether a mutation is deleterious is to conduct family 
studies that track whether the cardiomyopathy and the mutation present in a family segregate 
together; however, such family studies are often hindered by the lack of relatives available 
for evaluation and the phenomena of reduced penetrance and/or age-related penetrance. 
Functional characterization of mutant gene products may help determine the pathogenic 
effect of sequence variants identified in cardiomyopathy patients. However, given the large 
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number of novel putative pathogenic mutations still being discovered, it is impossible to 
expect timely functional characterization of all variants in the current labor-intensive in vitro 
and in vivo functional assays. Moreover, universally applicable ‘gold standard’ functional 
characterization assays do not exist for cardiomyopathy-associated proteins and a negative 
result in current assays may simply indicate the existence of novel and presently 
undetectable disease mechanisms.
Without ‘gold standard’ functional assays, reliable and accurate predictive algorithmic 
approaches that model the pathogenicity of novel mutations identified would be very useful. 
Sort Intolerant from Tolerant (SIFT) and Polymorphism Phenotype (PolyPhen) are two 
sequence homology-based software tools intended to predict the potential impact of a 
mutation on protein function [159,160]. While these tools are particularly useful for 
prioritizing research-based studies of specific mutations, they should be used cautiously for 
interpreting the significance of novel genetic variants identified in a clinical genetic test. An 
analysis of nearly 45,000 nonsynonymous polymorphisms by SIFT and PolyPhen 
demonstrated that each program independently predicted approximately a third of common 
polymorphisms to be deleterious or damaging with approximately 60% concordance [161]. 
This may indicate that these programs are overly sensitive and likely to label many benign 
variants as potentially disease-associated, resulting in false-positive interpretations of genetic 
test results. These tools should undergo rigorous evaluation in a disease- and gene-specific 
fashion by comparing the predictions produced for proven disease-associated mutations to 
the predictions for known benign variants in the same genes.
With whole-genome scale sequencing technologies promising affordable and overwhelming 
amounts of sequence data, resolving the significance of new genetic variants will continue to 
be a major challenge. Extending sequencing from protein coding regions to non-protein-
coding regions of genes, including intronic regions, promoters, 5′ and 3′ untranslated 
regions, may identify synonymous deleterious variants that alter splicing or gene-expression 
levels, but as noncoding regions tend to harbor extensive genetic variability, such expanded 
analyses will greatly increase the number of VUSs identified. Until the extent of variability 
in relevant genes is cataloged and characterized, the interpretation of VUSs will continue to 
be a real challenge to interpretation of genetic testing for cardiomyopathies.
Conclusion
Over the past 20 years, there has been an increasing appreciation for the genetic basis of 
cardiomyopathies. The recognition of a number of clinically distinct cardiomyopathies 
(HCM, DCM, RCM, ARVC and LVNC) has led to intense investigation for underlying 
genetic defects. The genetic defects in HCM are the best characterized to date, with up to 
65% of patients having identifiable disease-causing mutations. Similarly robust genetic 
testing for ARVC can identify an estimated 50–55% of ARVC patients. However, the 
collective testing of more than 20 genes identifies a genetic cause for only approximately 
25% of idiopathic DCM patients. Since RCM and LVNC are relatively rare, studies 
determining the prevalence of mutations in these populations have not been performed. 
Thus, genetic testing for cardiomyopathies is currently limited by poor sensitivity for disease 
diagnosis, although the specificity of these tests is high. Despite these limitations, 
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professional recommendations have been published for the use of genetic testing in the 
diagnosis of familial HCM, ARVC and DCM, with the caveat that negative test results do 
not rule out the presence of a heritable cardiomyopathy [1,108–110]. Furthermore, 
genotype–phenotype correlations are not well understood at this time, limiting the utility of 
genetic testing for prediction of disease course or severity in an affected individual and 
making genetic testing primarily useful for identifying the presence of known familial 
mutations in at-risk family members in order to target appropriate relatives for careful follow 
up. Although mutation- and disease-specific therapies have been suggested and may become 
available in the future, genetic testing for this use is currently premature [162].
Expert commentary
The diagnosis of cardiomyopathy often begins with the identification of characteristic 
structural and functional abnormalities of the heart, typically using clinical imaging 
techniques, such as echocardiography or MRI. Such findings should prompt a thorough 
discussion between the physician and the patient, directed at elucidating the clinical 
consequences and possible etiologies for the abnormalities. In the absence of other causative 
factors, the diagnosis of familial cardiomyopathy must be considered. The interplay between 
increasing diagnostic awareness and significant advances in DNA sequencing technology 
has revealed a rapidly expanding list of genes that cause heritable cardiomyopathies.
At present, the tools available to the clinician for diagnosing familial cardiomyopathies have 
outstripped the therapeutic options available for their treatment, although it is exciting to 
imagine a future in which the diagnosis of gene-specific abnormalities could prompt the 
initiation of gene-specific therapy. Nor is there currently a sufficient understanding of the 
relationship between the genotype and phenotype of these disorders to support the 
differential use of existing therapies for patients with familial cardiomyopathy. Thus, a 
patient with DCM due to a mutation in MYH7 is treated using the same clinical approach as 
a patient with DCM secondary to viral myocarditis. The true clinical benefit to making a 
diagnosis of familial cardiomyopathy arises from the possibility of identifying relatives of 
the proband who are presymptomatic and initiating life-extending evidence-based therapies.
Through little fault of their own, the vast majority of clinicians remain unaware of the ever-
lengthening list of disease-causing mutations, let alone how to pursue their identification. 
The National Center for Biotechnology Information (NCBI) maintains a medical genetics 
website that compiles much of the present knowledge regarding the genetic causes of 
heritable disorders, including cardiomyopathies [301]. A search for ‘cardiomyopathy’ on the 
website reveals results organized by type of cardiomyopathy followed by lists of the known 
causative mutations (reviewed in TABLE 5). Many of the listed genes are accompanied by 
links to the contact information for clinical laboratories that will perform sequence analysis 
for the chosen mutation. While not completely contemporary, GeneTests is an extensive and 
important – if somewhat daunting – resource for clinicians interested in evaluating a patient 
for familial cardiomyopathy. In an effort to simplify the diagnostic interface, multiple 
laboratories have begun offering ‘cardiomyopathy panels’ based on the cardiac phenotype 
(e.g., DCM, HCM and ARVC) that use gene chips to screen a single sample for almost all of 
the mutations known to cause the cardiomyopathy of interest. Such an approach removes the 
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onus from the provider for searching either their memory or the internet for a list of the 
genes to be sequenced. These sequencing services are available from both academically 
affiliated (Harvard/ Partners Healthcare) and commercial (Correlagen Diagnostics, Inc., 
GeneDx, PGxHealth/FAMILION) laboratories. Chip-based assays have also been developed 
and may provide cheaper and faster diagnosis of HCM [144,145] and DCM [146], although 
with some limitations. It seems likely that the availability of such efficient and user-friendly 
testing will increase the frequency with which clinicians will seek, and thus find, the 
diagnosis of familial cardiomyopathy.
Five-year view
It would be optimistic to predict that in 5 years we would recognize most of the genes and 
disease-causing mutations for the five clinically distinct cardiomyopathies. However, 
continued research efforts will probably result in a substantial increase in the number of 
genes identified that are associated with familial cardiomyopathies. It is expected that the 
identification of additional genes and the application of recent technical advances, such as 
next-generation sequencing and microarray-based ‘resequencing’ to genetic diagnosis (as 
recently reviewed in [4]) will lead to dramatic improvement in the clinical sensitivity and 
cost–effectiveness of genetic testing for cardiomyopathies. We also predict that the 
bioinformatic and functional approaches reviewed in this article will become valuable in 
distinguishing novel pathogenic mutations from novel benign variants. This will be assisted 
by the rapid increase in our understanding of the genetic variation in the human genome in 
both health and disease by large-scale resequencing efforts, which are currently underway or 
have yet to begin. While not discussed in detail here, genetic modifiers of HCM have been 
identified, which when present are associated with a greater severity of disease in some 
studies [4,163–165]. In the future, more conclusive genotype–phenotype relationships may 
be made by identifying mutations not only in specific structural genes but also in such 
comodifier genes, which may drive specific treatment modalities based on the spectrum of 
mutations identified. Lastly, we predict the identification and experimental application of 
mutation specific therapy to cardiomyopathies. For example, the use of drugs to read-
through specific truncation mutations has been applied to Duchenne muscular dystrophy and 
cystic fibrosis [162,166]; its application to cardiomyopathies is certain to be tested in the 
near future. The prospect of specific therapies guided by mutation testing or targeting 
individual mutations is exciting given the lack of currently available therapies for most of 
the cardiomyopathies.
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• Cardiomyopathies are a clinically and genetically heterogeneous group 
of heart muscle diseases associated with mechanical and/or electrical 
dysfunction that may predispose patients to sudden cardiac death.
• Over the last two decades, the association of specific genes involved 
with clinically distinct cardiomyopathies (hypertrophic 
cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, 
arrhythmogenic right ventricular cardiomyopathy and left ventricular 
noncompaction cardiomyopathy) has shed light onto the 
pathophysiology and identification of these diseases. Not all disease-
causing mutations have been identified, which currently limits the 
sensitivity of these tests. Mutations in the same genes may also 
underlie different cardiomyopathies.
• With relatively cheaper and quicker whole-genome scale sequencing 
technologies promising overwhelming amounts of sequence data on the 
horizon, interpreting and resolving the significance of rare genetic 
variants will become a major challenge on which to focus.
• Without ‘gold standard’ assays that can prove a pathogenic effect, it 
can be difficult to differentiate between novel disease-causing 
mutations and rare benign genetic variation that is seen in the general 
population.
• Clinical genetic tests for several cardiomyopathies are commercially 
available. The major clinical utility shared by the different 
cardiomyopathies is the ability to accurately predict the risk for a 
family member for developing a familial cardiomyopathy who 
currently has little or no clinical evidence of disease.
• The role of genetic counseling in genetic testing has never been more 
important because of our incomplete understanding of the genetic basis 
of cardiomyopathies that continues to evolve. Patients with 
cardiomyopathy need guidance to understand the complex and evolving 
issues of testing utility, sensitivity, analytic validity and implications of 
possible testing results.
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Figure 1. Arrhythmogenic right ventricular cardiomyopathy
(A) Cardiac MRI reveals fibrofatty infiltration of the right ventricular free wall, with some 
involvement of the left ventricle. (B) Electrocardiogram in normal sinus rhythm exhibiting a 
repolarization abnormality characteristic of arrhythmogenic right ventricular 
cardiomyopathy, known as the ‘epsilon wave’ (indicated by arrows). (C) Electrocardiogram 
demonstrating ventricular tachycardia originating from the RV. RV: Right ventricle; VT: 
Ventricular tachycardia.
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Figure 2. Selected proteins involved in the pathogenesis of cardiomyopathies shown in the 
context of their respective cellular structures
Cardiomyopathies are a genetically heterogeneous group of diseases that result from 
dysfunction in a multitude of diverse biological processes, including contractile force 
generation and transmission, mechanical stretch sensing, nuclear structure and function, and 
ion channel function.
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Figure 3. Hypertrophic cardiomyopathy (HCM)
(A) Transthoracic echocardiogram in the apical four-chamber view demonstrates 
pronounced thickening of the distal interventricular septum and lateral wall of the left 
ventricle, consistent with the apical variant of HCM. (B) 12-lead electrocardiogram with 
evidence of left ventricular hypertrophy and deep T-wave inversions throughout the 
precordium, characteristic of apical variant HCM. (C) Transthoracic echocardiogram in the 
apical long-axis view demonstrates left ventricular hypertrophy, most pronounced in the 
interventricular septum, consistent with HCM. (D) Transthoracic echocardiogram using 
Doppler signal in the left ventricular outflow tract reveals a resting pressure gradient of 85 
mmHg between the cavity of the left ventricle and the aortic root. (E) This pressure gradient 
augments to 213 mmHg with Valsalva maneuver, characteristic of the dynamic left 
ventricular outflow tract gradient of obstructive HCM.
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Figure 4. Dilated cardiomyopathy
(A) Transthoracic echocardiogram in the parasternal long-axis view demonstrates dilation of 
the left ventricle. (B) M-mode echocardiography from the same view reveals markedly 
diminished systolic thickening of the myocardium.
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Figure 5. Left ventricular noncompaction cardiomyopathy
(A)Transthoracic echocardiogram in the parasternal short-axis view reveals prominent 
myocardial noncompaction involving all segments of the left ventricle other than the 
interventricular septum. (B) Use of injectable echocardiographic contrast in the same view 
further defines the structural abnormalities.
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Table 1
Genetic cardiomyopathies.
Disease Inheritance pattern Estimated prevalence Patients with 
mutations based on 
testing known 
causative genes (%)
Arrhythmogenic right ventricular 
cardiomyopathy
Autosomal dominant 1:5000 50–55
Dilated cardiomyopathy Autosomal dominant, autosomal recessive, 
X-linked
1:2500 ~25
Hypertrophic cardiomyopathy Autosomal dominant, autosomal recessive, 
X-linked
1:500 35–65
Left ventricular noncompaction 
cardiomyopathy
Autosomal dominant, X-linked Unknown 20–25
Restrictive cardiomyopathy Autosomal dominant Unknown Unknown
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Table 2
Genetic causes of arrhythmogenic right ventricular cardiomyopathy, left ventricular noncompaction 
cardiomyopathy and restrictive cardiomyopathy.
Protein Frequency in patients (%) Ref.
Restrictive cardiomyopathy
β-myosin heavy chain Unknown [104]
Cardiac troponin I Unknown [99,104]
Cardiac troponin T Unknown [100,102,167]
α-cardiac actin Unknown [100]
Left ventricular noncompaction cardiomyopathy
β-myosin heavy chain 13 [92,93]
α-cardiac actin 3 [92]
Cardiac troponin T <2 [92]
LIM domain-binding protein 3 (Cypher/ZASP) Unknown [87]
α-dystrobrevin Unknown [86]
Tafazzin Unknown [86]
Lamin A/C Unknown [168]
Arrhythmogenic right ventricular cardiomyopathy
Plakophilin 2 25–35 [5,17]
Desmoplakin 5 [5,17]
Desmoglein 2 5 [5,17]
Desmocollin 2 Rare [5,17]
Plakoglobin Rare [5,17]
TGFβ3 Rare [5,23]
Transmembrane protein 43 Unknown [24]
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Table 3
Genetic causes of hypertrophic cardiomyopathy and hypertrophic cardiomyopathy phenocopy diseases.




MYH7 β-myosin heavy chain 15–25 [130,169–171]
MYBPC3 Myosin-binding protein C 15–25 [130,169–171]
TNNT2 Cardiac troponin T <5 [130,169–171]
TPM1 α-tropomyosin <5 [130,169–171]
TNNI3 Cardiac troponin I <5 [130,169–171]
MYL2 Myosin regulatory light chain <2 [130,169–171]
MYL3 Myosin essential light chain Rare [130,169–171]
ACTC α-cardiac actin Rare [130,169–171]
TNNC1 Cardiac troponin C Rare [171,172]
TTN Titin Rare [169,173]
MYH6 α-myosin heavy chain Rare [169,174]
LDB3 LIM binding domain 3 (Cypher/ZASP) Rare [175]
CSRP3 Muscle LIM protein Rare [175,176]
TCAP Telethonin Rare [175,177]
VCL Vinculin/metavinculin Rare [175,178,179]
ACTN2 α-actinin 2 Rare [175]
MYOZ2 Myozenin 2 Rare [180]
ANKRD1 Ankyrin repeat domain 1 Rare [181]
JPH2 Junctophilin-2 Rare [43]
PLN Phospholamban Rare [44,45]
Hypertropic cardiomyopathy phenocopy diseases (metabolic/ infiltrative diseases)
GLA α-galactosidase A (Anderson-Fabry disease) <5 [182,183]
PRKAG2 AMP-activated protein kinase subunit (WPW with LVH) Rare [133,169,184]
LAMP2 Lysosome-associated membrane protein 2 (Danon syndrome) Rare [133,185]
HCM: Hypertrophic cardiomyopathy; LVH: Left ventricular hypertrophy; WPW: Wolff–Parkinson–White syndrome.
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Table 4
Genetic causes of dilated cardiomyopathy.
Gene Description Frequency in DCM patients (%) Ref.
ACTC α-cardiac actin Rare [57,186–188]
ANKRD1 Ankyrin repeat domain 1 <5 [189,190]
LDB3 LIM domain-binding protein 3 (Cypher/ZASP) <5 [87,141]
LMNA Lamin A/C 6 [135,136,191–196]
MYBPC3 Myosin-binding protein C <5 [197–200]
MYH7 β-myosin heavy chain <5 [58,141,197,201]
PLN Phospholamban Rare [201–203]
SCN5A Sodium channel <3 [204–206]
TNNC1 Cardiac troponin C Rare [61]
TNNI3 Cardiac troponin I Rare [71,207]
TNNT2 Cardiac troponin T <2 [58,60,61,141,201]
TPM1 α-tropomyosin Rare [59]
TTN Titin Rare [208]
MYH6 α-myosin heavy chain Rare [174]
CSRP3 Muscle LIM protein Rare [141,209]
TCAP Telethonin Rare [141,177]
VCL Vinculin/metavinculin Rare [201,210]
ACTN2 α-actinin 2 Rare [211]
DES Desmin Rare [188,212,213]
SGCD δ-sarcoglycan Rare [214–216]
ABCC9 ATP-binding cassette C member 9 Rare [217]
EYA4 Eyes-absent 4 Unknown [218]
TMPO Thymopoietin Rare [219]
PSNE1 Presenilin 1 Rare [220]
PSNE2 Presenilin 2 Rare [220]
DMD Dystrophin Rare [142,199,221,222]
TAZ Tafazzin Rare [86,223,224]
DCM: Dilated cardiomyopathy.
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Table 5
Current clinically available genetic testing modalities for the diagnosis of familial cardiomyopathies.
Gene affected Description Analysis performed† Laboratories performing test‡ (n)
Arrhythmogenic right ventricular cardiomyopathy
DSC2 Desmocollin-2 1, 7, 10 6
DSG2 Desmoglein-2 1, 7, 10 5
DSP Desmoplakin 1, 2, 7 6
JUP Junction plakoglobin 1 2
PKP2 Plakophilin-2 1, 5, 7, 10 9
RYR2 Ryanodine receptor 2 1, 3, 4, 10 4
TGFB3 TGFβ3 1 1
TMEM43 Transmembrane protein 43 1, 2, 7 7
Left ventricular noncompaction cardiomyopathy§
DTNA Dystrobrevin α 1, 6, 7 3
LDB3 Lim domain-binding protein 3 1, 7 2
LMNA Lamin-A/C 1, 3–5, 7 17
TAZ Tafazzin 1, 6, 7 3
Dilated cardiomyopathy
ABCC9 ATP-binding cassette 1, 7 1
ACTC1 Actin, α cardiac muscle 1 1, 7 4
ACTN2 α-actinin 2 1, 7 1
CSRP3 Cysteine and glycine-rich protein 3 1, 7 1
DES Desmin 1, 7 2
DMD Dystrophin 1–10 37
LDB3 Lim domain-binding protein 3 1, 7 2
LMNA Lamin-A/C 1, 3–5, 7 17
MYBPC3 Myosin-binding protein C, cardiac type 1, 7, 10 6
MYH7 Myosin 7 1, 7, 10 8
PLN Cardiac phospholamban 1, 7 1
SCN5A Sodium channel protein type 5, subunit α 1, 5, 7, 10 8
SGCD Sarcoglycan, δ 1, 7, 10 3
TAZ Tafazzin 1, 6, 7 6
TCAP Telethonin 1, 7 2
TNNI3 Troponin I, cardiac muscle 1, 2, 6, 7, 10 6
TNNT2 Troponin T, cardiac muscle 1, 2, 7, 10¶ 8
TPM1 Tropomyosin α-1 chain 1, 7, 10 4
TTN Titin 2 1
VCL Vinculin 1, 7 1
Hypertrophic cardiomyopathy













Callis et al. Page 40
Gene affected Description Analysis performed† Laboratories performing test‡ (n)
Arrhythmogenic right ventricular cardiomyopathy
ACTC1† Actin, α cardiac muscle 1 1, 5, 7 6
CSRP3† Cysteine and glycine-rich protein 3
MYBPC3† Myosin-binding protein C, cardiac type 1, 2, 5, 7, 10 11
MYH7† Myosin heavy chain 7, cardiac muscle, β 1, 2, 5, 7, 10 10
MYL2 Myosin light chain 2, regulatory, cardiac, slow 1, 5, 7 7
MYL3 Myosin light chain 3, ventricular, slow 1, 5, 6, 7 8
TCAP† Telethonin 1, 7 2
TNNC1 Troponin C, cardiac muscle 1, 5, 7 2
TNNI3† Troponin I, cardiac muscle 1, 2, 5, 7, 10 9
TNNT2† Troponin T, cardiac muscle 1, 2, 5, 7, 10§ 10
TPM1† Tropomyosin α-1 chain 1, 5, 7, 10 8
TTN† Titin 2 1
Restrictive cardiomyopathy
TNNI3† Troponin I, cardiac muscle 1, 2, 5, 7, 10 3
†
Types of analysis: 1: Analysis of entire coding region; 2: Sequence analysis of select exons; 3: Linkage analysis.; 4: Mutation scanning of select 
exons; 5: Deletion, duplication analysis; 6: Carrier testing; 7: Prenatal diagnosis; 8: FISH-metaphase; 9: FISH-anaphase; 10: Mutation scanning of 
entire coding region.
‡
Covered in multiple disease phenotypes. The currently available testing methods were compiled from GeneTests. The designation of clinically 
available was made if the laboratory self-reported as being either a US CLIA-licensed laboratory or a non-US clinical laboratory. Verification must 
be made directly with the laboratory.
§
Testing for left ventricular noncompaction cardiomyopathy would include MYH7 as well, although not noted in GeneTests.
¶
Testing procedures appear to be different for TNNT2 depending on what phenotype they are ordered for. Verification must be made directly with 
the laboratories performing the analysis.
Data from [140].
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